All In Biotech

Drug Trial Radar · NCT06041386

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

A Prospective, Real-World, Interventional Study To Evaluate The Effect Of Mepolizumab On Achieving Clinical Remission In Participants With Severe Asthma

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

177

Actual

Start

Mar 20, 2024

Primary completion

Feb 12, 2026

Study completion Mar 31, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).

Conditions

  • Asthma

Interventions

  • MepolizumabDrug

    Mepolizumab will be prescribed based on physician decision.

  • SpirometryOther

    Lung function via spirometry will be collected.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage (%) of Participants Achieving 4-Component Clinical RemissionTime frame: At month 12

Locations

65 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    La Jolla, California

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Aurora, Colorado

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Homestead, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Plantation, Florida

  • GSK Investigational Site

    Adairsville, Georgia

  • GSK Investigational Site

    Columbus, Georgia

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Owensboro, Kentucky

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Glenn Dale, Maryland

  • GSK Investigational Site

    Towson, Maryland

  • GSK Investigational Site

    Ann Arbor, Michigan

  • GSK Investigational Site

    Linwood, Minnesota

  • GSK Investigational Site

    Rochester, Minnesota

  • GSK Investigational Site

    Henderson, Nevada

  • GSK Investigational Site

    Rochester, New York

  • GSK Investigational Site

    Schenectady, New York

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Union, South Carolina

  • GSK Investigational Site

    Cypress, Texas

  • GSK Investigational Site

    Kerrville, Texas

  • GSK Investigational Site

    McKinney, Texas

  • GSK Investigational Site

    Kortrijk, Belgium

  • GSK Investigational Site

    Liège, Belgium

  • GSK Investigational Site

    Calgary, Alberta, Canada

  • GSK Investigational Site

    Calgary, Alberta, Canada

  • GSK Investigational Site

    Winnipeg, Manitoba, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Brest, France

  • GSK Investigational Site

    Cannes, France

  • GSK Investigational Site

    Lille, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Strasbourg, France

  • GSK Investigational Site

    Toulouse, France

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.